TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16359953

Group type: EXPERIMENTAL
Intervention: Removal of cryodamaged blastomeres (in the study group) during frozen-thawed ET
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no removal of lysed blastomeres) during frozen-thawed ET
Number of subjects: 88
Study: 12111046

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy combined with Dietary Intervention (HRT+DIET)
Number of subjects: 24
Study: 10621764

Group type: EXPERIMENTAL
Intervention: Emergency telephone support in addition to treatment as usual (intervention group)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 827
Study: 8901820

Group type: EXPERIMENTAL
Intervention: Plasma fractions from preeclamptic women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma fractions from normal pregnant women
Number of subjects: 0
Study: 1813429

Group type: EXPERIMENTAL
Intervention: Modified double-flared technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double-flared technique
Number of subjects: 60
Study: 6729651

Group type: EXPERIMENTAL
Intervention: High-dose weekly fractionation regimen
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional daily fractionation schedule
Number of subjects: 83
Study: 30847689

Group type: EXPERIMENTAL
Intervention: Food exposure session in a partial hospital eating disorder center
Number of subjects: 42
Study: 30195243

Group type: EXPERIMENTAL
Intervention: Positive affect intervention (n=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Attention-control condition (n=55)
Number of subjects: 110
Study: 27328808

Group type: EXPERIMENTAL
Intervention: CB12 (0.3% zinc acetate and 0.025% chlorhexidine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 34
Study: 24343275

Group type: EXPERIMENTAL
Intervention: Microencapsulated sodium butyrate (MSB) 300 mg daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 22404668

Group type: EXPERIMENTAL
Intervention: Hypothermia as neuroprotection during surgery
Number of subjects: 1001
Study: 19938151

Group type: EXPERIMENTAL
Intervention: Hcy‐lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alpha‐lipoic acid (alpha‐LA) therapy (1200 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 19099975

Group type: EXPERIMENTAL
Intervention: Psychological stress group (ACS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-psychological stress group (ACS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ACS group
Number of subjects: 100

Group type: COMPARATOR
Intervention: SA group
Number of subjects: 100
Study: 16041896

Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral bereavement coping group intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Individual psychotherapy upon request
Number of subjects: 235
Study: 12443969

Group type: EXPERIMENTAL
Intervention: 1.2% C31G hydroxyethyl cellulose (HEC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9) (Gynol II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HEC vehicle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.2% C31G HEC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9)
Number of subjects: 60
Study: 10434220

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol vapor
Number of subjects: 91

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 91
Study: 7872875

Group type: EXPERIMENTAL
Intervention: selegiline hydrochloride (10 mg/d)
Number of subjects: 800

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800
Study: 2219469

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium vaccae (10^9 irradiation‐killed M. vaccae)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium vaccae
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 47
Study: 660709

Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis drugs and oral iron
Number of subjects: 21

Group type: COMPARATOR
Intervention: Anti-tuberculosis drugs only
Number of subjects: 21
Study: 31618176

Group type: EXPERIMENTAL
Intervention: 8 weeks of concurrent aerobic (60‐80% heart rate reserve) and resistance (40‐65% of 1RM) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 27748083

Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg plus MTX
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg plus MTX
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg plus MTX
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg plus MTX
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 378
Study: 26654721

Group type: EXPERIMENTAL
Intervention: Family meetings (FM)
Number of subjects: 0
Study: 23482645

Group type: EXPERIMENTAL
Intervention: HIV DNA vaccine (4 mg) coding for clade B Gag, Pol, and Nef and clade A, B, and C Env, followed by a replication-deficient adenovirus type 5 boost (10^10 particle units)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21490144

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: BCAA supplementation during phenylbutyrate therapy
Number of subjects: 14
Study: 19551673

Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as second choice
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as third choice
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fixed Combination (FC) therapy as first choice
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol FC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol FC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FC therapy overall
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol FC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prostaglandins dosing time
Number of subjects: 50
Study: 16710082

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral anticoagulants (target INR 2-3)
Number of subjects: 28
Study: 15451902

Group type: EXPERIMENTAL
Intervention: AS‐3201 at 5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS‐3201 at 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11408332

Group type: COMPARATOR
Intervention: Dyslexic subjects
Number of subjects: 0
Study: 9414368

Group type: EXPERIMENTAL
Intervention: Garments with different fastener types and locations
Number of subjects: 10
Study: 7997846

Group type: EXPERIMENTAL
Intervention: Moderately salt restricted diet
Number of subjects: 34
Study: 3073270

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon, type alpha (IFN) ointment, 7,000 Ul/gm
Number of subjects: 66

Group type: COMPARATOR
Intervention: Carbowax 4,000 (placebo)
Number of subjects: 66
Study: 31667901

Group type: EXPERIMENTAL
Intervention: Nanotextile (customized nanotextile)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Viscose (Tubifast™)
Number of subjects: 53
Study: 30506302

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 28601108

Group type: EXPERIMENTAL
Intervention: Active intervention with 5 group meetings, 9 personal motivational calls, 9 automated motivational calls
Number of subjects: 288
Study: 28578180

Group type: EXPERIMENTAL
Intervention: Frequency of social interactions with friends
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Perceived satisfaction with relationships
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Frequency of family interaction
Number of subjects: 178
Study: 23794185

Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Maxillary sinus clearance through middle meatal antrostomy (MMA)
Number of subjects: 29
Study: 21849912

Group type: EXPERIMENTAL
Intervention: Sprint-Interval Training (SIT) program: 6 35-m sprints at maximum effort with a 10-second recovery, performed in 2 sessions per week for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (traditional training without SIT)
Number of subjects: 15
Study: 19641928

Group type: EXPERIMENTAL
Intervention: Curved Cutter Stapler (CCS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Linear Stapler
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both CCS and Linear Stapler
Number of subjects: 60
Study: 17118480

Group type: EXPERIMENTAL
Intervention: Gliclazide treatment for 8 weeks
Number of subjects: 115
Study: 15001324

Group type: EXPERIMENTAL
Intervention: Combination of etanercept 25 mg (subcutaneously twice a week) and oral methotrexate (up to 20 mg every week)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Combination of etanercept and methotrexate
Number of subjects: 682

Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 682

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 682
Study: 11368288

Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 910 mg/m2
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 200 mg/m2
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 340 mg/m2
Number of subjects: 689

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 689
Study: 9040548

Group type: EXPERIMENTAL
Intervention: Large morning meals (AM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Large evening meals (PM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Large evening meals (PM) in period 1
Number of subjects: 10
Study: 7934153

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (4 puffs of 0.02 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intramuscular atropine (0.5 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (4 puffs)
Number of subjects: 29
Study: 3351153

Group type: COMPARATOR
Intervention: Indecainide 50 mg three times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indecainide 75 mg three times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indecainide 100 mg three times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indecainide
Number of subjects: 10
Study: 28966223

Group type: EXPERIMENTAL
Intervention: 12-week lifestyle modifications (combination of aerobic exercise training and dietary modification)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12-week lifestyle modifications
Number of subjects: 20
Study: 28489239

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate solution
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mupirocin ointment
Number of subjects: 65
Study: 24165901

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Local anesthetic (LA)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: TPVB and LA
Number of subjects: 145
Study: 23245290

Group type: EXPERIMENTAL
Intervention: 100 mg/m2 cisplatin once every 3 weeks (arm A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 40 mg/m2 cisplatin once per week (arm B)
Number of subjects: 55
Study: 20824851

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study: 17481748

Group type: EXPERIMENTAL
Intervention: Simultaneous assessment of B-type natriuretic peptide (BNP), cardiac troponin I (cTNI), and C-reactive protein (CRP)
Number of subjects: 305
Study: 16885989

Group type: EXPERIMENTAL
Intervention: Adjustable fortification (ADJ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard fortification (STD)
Number of subjects: 32
Study: 14664686

Group type: EXPERIMENTAL
Intervention: Standardized treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist as a random term
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study: 10936467

Group type: EXPERIMENTAL
Intervention: Capecitabine at a dose of 2.510 mg/m²/day (divided into two equal doses) given in an intermittent schedule (2 weeks on/1 week off)
Number of subjects: 0
Study: 9182140

Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Ascorbic acid level
Number of subjects: 528
Study: 12959305

Group type: EXPERIMENTAL
Intervention: Fenoterol dry powder capsules (DPC) 0.2 mg, 0.4 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fenoterol metered dose inhaler (MDI) 0.2 mg, 0.4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cumulative doses of fenoterol DPC (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cumulative doses of fenoterol MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Number of subjects: 24
Study: 3320307

Group type: EXPERIMENTAL
Intervention: Vincristine (0.025 mg/kg intravenously for eight dosages over 12 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: OKT3 monoclonal antibody (first 2 weeks after transplantation)
Number of subjects: 52
Study: 29621985

Group type: EXPERIMENTAL
Intervention: ReNACE psychoeducational intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: General educational programme
Number of subjects: 200
Study: 26937948

Group type: EXPERIMENTAL
Intervention: Continuous intravenous unfractionated heparin (5000-10000 units/day) until postoperative day 7 (POD7)
Number of subjects: 206

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ablative surgery and neck dissection without heparin
Number of subjects: 206
Study: 24747805

Group type: EXPERIMENTAL
Intervention: Ozone (0.30ppm) inhalation during 1 hour of exercise
Number of subjects: 30
Study: 24378268

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day for one month
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21074020

Group type: EXPERIMENTAL
Intervention: Full Patient Decision Aid (PtDA) containing information and values guidance
Number of subjects: 63

Group type: COMPARATOR
Intervention: Abridged Patient Decision Aid (PtDA) containing information only
Number of subjects: 63
Study: 18828077

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) pit pattern classification
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vascular pattern intensity (VPI)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of NBI pit pattern and VPI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NBI pit pattern
Number of subjects: 62
Study: 17273672

Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Prednisone (0.75 mg/kg/day)
Number of subjects: 22
Study: 14600548

Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 0
Study: 11339008

Group type: EXPERIMENTAL
Intervention: Chronic alcohol use (abstainers for 2-6 years)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 17
Study: 8637698

Group type: EXPERIMENTAL
Intervention: Single oral-dose azithromycin (20 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical tetracycline eye ointment for 6 weeks
Number of subjects: 64
Study: 1458621

Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze swabs
Number of subjects: 0
Study: 4025792

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia with 12-15 ml 0.25% plain bupivacaine and general anesthesia (flunitrazepam 1.5-2 mg, pancuronium bromide 0.1 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (droperidol 0.1-0.2 mg/kg, fentanyl 0.01 mg/kg, pancuronium bromide 0.1 mg/kg, thiopentone 100-150 mg)
Number of subjects: 50
Study: 31905097

Group type: EXPERIMENTAL
Intervention: Cervical spine high-velocity, low-amplitude thrust (HVLAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 50
Study: 29461363

Group type: EXPERIMENTAL
Intervention: 60 mm Hg capsule pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 70 mm Hg capsule pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mm Hg capsule pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90 mm Hg capsule pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mm Hg capsule pressure
Number of subjects: 30
Study: 26043861

Group type: EXPERIMENTAL
Intervention: 6 servings (96 g) of WG wheat
Number of subjects: 19

Group type: COMPARATOR
Intervention: 3 servings (48 g) of WG wheat
Number of subjects: 19
Study: 25461966

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) used as an adjunct to endodontic re-treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Endodontic re-treatment alone
Number of subjects: 21
Study: 22366285

Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasted exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 19771507

Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 234
Study: 18382132

Group type: EXPERIMENTAL
Intervention: Stamaril
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: VCFA
Number of subjects: 2514
Study: 15823450

Group type: EXPERIMENTAL
Intervention: SFC (50/100 microg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19753741

Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatments (six sessions of aluminum oxide microdermabrasion spaced over 7 to 10-day intervals)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatments (six sessions)
Number of subjects: 11
Study: 10369157

Group type: EXPERIMENTAL
Intervention: Flashbackers
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-flashbackers
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 87
Study: 7553254

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2 x 2.5 mg/d for 14 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metergoline (3 x 4 mg/d for 10 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Breastfeeding subjects (control group)
Number of subjects: 150
Study: 2045463

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7000139

Group type: EXPERIMENTAL
Intervention: Fluorescent sunlamps (B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluorescent UV‐A lamps (A + B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Germicidal lamps (A + B + C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Photochemotherapy with oral 8‐MOP followed by UV‐A (PUVA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsule followed by A + B (pUVAB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving no light
Number of subjects: 40
Study: 30471456

Group type: EXPERIMENTAL
Intervention: EUS-guided microforceps (TTNB)
Number of subjects: 114

Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 114
Study: 27787472

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (non-exercising)
Number of subjects: 22
Study: 25321886

Group type: EXPERIMENTAL
Intervention: Teen Options for Change (TOC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (Control)
Number of subjects: 49
Study: 24203541

Group type: EXPERIMENTAL
Intervention: Myoelectrically controlled functional electrical stimulation (MeCFES)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 21425515

Group type: EXPERIMENTAL
Intervention: Pajunk Sonoplex (echogenic) needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pajunk Uniplex (control) needle
Number of subjects: 60
Study: 20024850

Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease (IHD) with hypertension
Number of subjects: 160

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 160
Study: 17392352

Group type: EXPERIMENTAL
Intervention: Infliximab dose escalation (1.5 mg/kg increments)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Infliximab 3 mg/kg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Infliximab dose escalation(s)
Number of subjects: 329
Study: 15466998

Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=46)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-diabetic controls (n=50)
Number of subjects: 46
Study: 11137922

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography (DU)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 89
Study: 9875038

Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (Konakion MM) - 2 mg at birth, repeated at 7 and 30 days
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intramuscular vitamin K1 - 1 mg
Number of subjects: 156
Study: 8040759

Group type: EXPERIMENTAL
Intervention: Intensive therapy with an external insulin pump or at least three daily insulin injections, together with frequent daily blood-glucose monitoring
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional therapy with one or two daily insulin injections and once-daily monitoring
Number of subjects: 195
Study: 2723103

Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse (20 ml, twice daily for 6 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Hydroalcohol control
Number of subjects: 107
Study: 780039

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (10 to 20 mg, four times daily for 180 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31434541

Group type: EXPERIMENTAL
Intervention: MEN Count intervention
Number of subjects: 454

Group type: COMPARATOR
Intervention: Attention comparison condition focused on stress reduction
Number of subjects: 454
Study: 28615007

Group type: EXPERIMENTAL
Intervention: Rhythm-centred music making (RMM) intervention, 10 weekly sessions
Number of subjects: 54